Winthrop U.S. (a business of Sanofi-Aventis U.S. LLC) is recalling approximately 19,580 vials of Docetaxel injection concentrate (20 mg/mL, 1 mL vial). This prescription chemotherapy medication is being recalled because certain vials may be superpotent, containing a higher concentration of the drug than what is listed on the label. Patients using these specific vials from the affected lots may be at risk of receiving an unintended higher dose. Consumers should contact their healthcare provider or pharmacist immediately for guidance and return any unused vials to the pharmacy.
The drug vials are over-concentrated or 'superpotent,' which means patients may receive a higher dose of chemotherapy than prescribed. This can lead to increased severity of side effects or potentially toxic reactions.
Return to pharmacy for refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.